Summary of Study ST001333
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000910. The data can be accessed directly via it's Project DOI: 10.21228/M82H5K This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001333 |
| Study Title | Huntington’s Disease Genotype Suppresses Global Manganese-Responsive Processes |
| Study Type | Untargeted metabolomics analysis |
| Study Summary | Global untargeted metabolomics studies performed in the striatum tissue, the brain region most sensitive to neurodegeneration in Huntington’s Disease, to investigate global Mn-dependent and Mn-responsive biology following various Mn exposures in a mouse model of HD. |
| Institute | Vanderbilt University |
| Department | Chemistry |
| Laboratory | Center for Innovative Technology |
| Last Name | Codreanu |
| First Name | Simona |
| Address | 1234 Stevenson Center Lane |
| simona.codreanu@vanderbilt.edu | |
| Phone | 6158758422 |
| Submit Date | 2020-03-27 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-09-29 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR001422 |
| Treatment Summary: | This study utilized three Mn exposure paradigms: 1) a single subcutaneous exposure of either a 1% solution of MnCl2•4(H2O) in filtered MilliQ water at 50 mg/kg body weight or vehicle (filtered water), 2) a 1-week, and 3) 20-week chronic exposure. The 1-week exposure is a previously published week-long exposure protocol (intermittent injections given on days 0, 3 and 6, with sacrifice on day 7) known to elevate brain Mn levels1. The 20-week exposure is a twice weekly injection (Mondays and Thursdays) based on the estimated half-life of 3.5 days for Mn administered via this route and pilot work suggesting the absence of observable toxicity with this exposure paradigm (including no weight loss or physical signs of distress). |
| Treatment Compound: | Mn |
| Treatment Dose: | 0, 5, 15, 50 mg/kg body weight |
